Trial Profile
Herceptin in patients with advanced or metastatic salivary gland carcinomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Salivary gland cancer
- Focus Therapeutic Use
- 14 Apr 2017 Status changed from active, no longer recruiting to completed.
- 10 Sep 2005 New trial record.